Thiazolidinediones and hepatic fibrosis: don't wait too long
- 16 February 2006
- Vol. 55 (7) , 917-919
- https://doi.org/10.1136/gut.2005.085399
Abstract
Lack of effect of delayed thiazolidinedione treatment may imply that these drugs are of limited efficacy in hepatic fibrosis, and that treatment of chronic liver disease might be successful only if the therapy were started very earlyKeywords
This publication has 24 references indexed in Scilit:
- Cell Type-Specific Intervention of Transforming Growth Factor β/Smad Signaling Suppresses Collagen Gene Expression and Hepatic Fibrosis in MiceGastroenterology, 2005
- Steatosis: Co-factor in Other Liver Diseases *Hepatology, 2005
- The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activationThe FASEB Journal, 2005
- Liver fibrosisJournal of Clinical Investigation, 2005
- Adipogenic Transcriptional Regulation of Hepatic Stellate CellsJournal of Biological Chemistry, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004
- Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate CellsJournal of Biological Chemistry, 2004
- Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined dietBiochemical and Biophysical Research Communications, 2004
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡Hepatology, 2004
- Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazoneHepatology, 2003